CTMX
NASDAQCytomX Therapeutics Inc.
Price$2.94-0.04 (-1.17%)
01:30 PM07:45 PM
News · 26 weeks44-44%
2025-12-142026-06-07
Mix3090d
- SEC Filings12(40%)
- Other6(20%)
- Insider4(13%)
- Earnings3(10%)
- Offering3(10%)
- Analyst2(7%)
Latest news
25 items- SECSEC Form 8-K filed by CytomX Therapeutics Inc.8-K - CytomX Therapeutics, Inc. (0001501989) (Filer)
- PRCytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer- Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX's PROBODY® and Regeneron's Veloci-Bi® platforms - - CytomX to receive $37 million target selection payment for two additional programs selected - - Regeneron secures option to select up to 6 additional future targets bringing total potential target nomination, research, development, regulatory and sales-based milestones covered under the collaboration to up to approximately ~$4 billion - SOUTH SAN FRANCISCO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX) today announced an expansion of its collaboration and licensing agree
- PRCytomX Therapeutics to Present at Upcoming June Investor ConferencesSOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in June. Jefferies Global Healthcare ConferenceDate: Thursday, June 4, 2026 Fireside Chat: 3:10 p.m. ETLocation: New York, NY Goldman Sachs 47th Annual Global Healthcare ConferenceDate: Wednesday, June 10, 2026Fireside Chat: 9:20 a.m. ETLocation: Miami, FL A live webcast of the presentation will be available on the Events and Presentations page of CytomX's website at www.cytomx.com. In addition, management will be available for one-o
- ANALYSTWolfe Research initiated coverage on CytomX Therapeutics with a new price targetWolfe Research initiated coverage of CytomX Therapeutics with a rating of Outperform and set a new price target of $6.00
- PRCytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory AffairsSOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs. In this role, Dr. Gokhale will lead CytomX's global regulatory strategy and oversee regulatory engagement to support the continued advancement of the Company's PROBODY® pipeline through clinical development and toward potential commercialization. "Mamata brings deep global regulatory expertise and a proven track record of advancing oncology assets through late-stage development, global approvals and commercializ
- SECAmendment: SEC Form SCHEDULE 13G/A filed by CytomX Therapeutics Inc.SCHEDULE 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by CytomX Therapeutics Inc.SCHEDULE 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)
- PRCytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update- Positive data announced from Phase 1 Dose Expansion Study of varsetatug masetecan ("Varseta-M") EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - Enrollment of 40 patients in Varseta-M Dose Optimization completed; data update expected in 2H 2026 to inform monotherapy dose selection and potential registrational trial in late line CRC - - Varseta-M Phase 1 study evaluating combination with bevacizumab is ongoing with initial data expected by 1H 2027; Phase 1/2 Varseta-M chemotherapy combination study to be initiated in 2H 2026 - - Initiation of Phase 1 expansion cohort(s) in non-CRC indications planned for 2H 2026 - - Company to host conference call today at 5 p.m
- SECCytomX Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - CytomX Therapeutics, Inc. (0001501989) (Filer)
- SECSEC Form 10-Q filed by CytomX Therapeutics Inc.10-Q - CytomX Therapeutics, Inc. (0001501989) (Filer)
- SECSEC Form DEFA14A filed by CytomX Therapeutics Inc.DEFA14A - CytomX Therapeutics, Inc. (0001501989) (Filer)
- SECSEC Form DEF 14A filed by CytomX Therapeutics Inc.DEF 14A - CytomX Therapeutics, Inc. (0001501989) (Filer)
- PRCytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report first quarter financial results on Thursday, May 7, 2026, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT. Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX's website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to jo
- SECSEC Form PRE 14A filed by CytomX Therapeutics Inc.PRE 14A - CytomX Therapeutics, Inc. (0001501989) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by CytomX Therapeutics Inc.SCHEDULE 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)
- INSIDERSEC Form 4 filed by Chu Yu-Waye4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
- INSIDERSEC Form 4 filed by Mccarthy Sean A.4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
- INSIDERSEC Form 4 filed by Belvin Marcia4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
- INSIDERSEC Form 4 filed by Ogden Christopher4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
- SECSEC Form 8-K filed by CytomX Therapeutics Inc.8-K - CytomX Therapeutics, Inc. (0001501989) (Filer)
- SECSEC Form 424B5 filed by CytomX Therapeutics Inc.424B5 - CytomX Therapeutics, Inc. (0001501989) (Filer)
- PRCytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded WarrantsSOUTH SAN FRANCISCO, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the pricing of an underwritten public offering of 45,990,567 shares of its common stock at a price to the public of $5.30 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,179,245 shares of common stock. The gross proceeds to CytomX from the offering are expected to be $250 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, CytomX granted the underwriters a 30-day option to purchase up to an additiona
- SECSEC Form 424B5 filed by CytomX Therapeutics Inc.424B5 - CytomX Therapeutics, Inc. (0001501989) (Filer)
- PRCytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsSOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it has commenced an underwritten public offering of $250.0 million of shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants. In addition, CytomX expects to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering m
- SECSEC Form S-3ASR filed by CytomX Therapeutics Inc.S-3ASR - CytomX Therapeutics, Inc. (0001501989) (Filer)
CTMX FAQ
7 questionsWhat does CytomX Therapeutics Inc. do?
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse...Where does CTMX stock trade?
CytomX Therapeutics Inc. (CTMX) is listed on NASDAQ.What sector and industry is CTMX in?
CytomX Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did CytomX Therapeutics Inc. go public?
CytomX Therapeutics Inc. (CTMX) completed its IPO in 2015.What are analysts saying about CTMX?
CytomX Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Outperform with a $600.00 price target on 2026-05-19. Recent price targets range from $250.00 to $1200.00.What companies are similar to CTMX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare CTMX side-by-side with any of them on Quantisnow.How can I track CTMX on Quantisnow?
Quantisnow aggregates CytomX Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CTMX to receive live email and push alerts on every new disclosure.